ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis

IDrugs

Volumn 11, Issue 11, 2008, Pages 827-840

  Nemeth, E F ^a  

^a MetisMedica   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE[1-31] DERIVATIVE; PARATHYROID HORMONE[1-31][27 LEUCINE] AMIDE 22,26 AMIDE; PARATHYROID HORMONE[1-31]AMINE; PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE[1-34]AMINE; RECOMBINANT PARATHYROID HORMONE; UNCLASSIFIED DRUG; ZT 031;

BONE DENSITY; CANCELLOUS BONE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORTICAL BONE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXPERIMENTAL MODEL; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOTENSION; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANABOLIC AGENTS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; PATENTS AS TOPIC; PEPTIDES, CYCLIC; PRIMATES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 55549134654     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. 237625 Small bone-building fragments of parathyroid hormone: New therapeutic agents for osteoporosis. Whitfield JF, Morley P TRENDS PHARMACOL SCI 1995 16 11 382-386
2. 290236 Solid phase peptide synthesis. I. The synthesis of a tetrapeptide Merrifield RB J AM CHEM SOC 1963 85 14 2149-2154
3. 323095 Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Sato M, Zeng GQ, Turner CH ENDOCR 1997 138 10 4330-4337
4. 408551 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O et al NEW ENGL J MED 2001 344 19 1434-1441
5. 483145 Zelos secures funding for clinical trials Zelos Therapeutics PRESS RELEASE 2003 March 24
6. 2 on bone formation and mechanical strength in ovariectomized rats. Morley P, Whitfield JF, Willick GE, Ross V, MacLean S, Barbier JR, Isaacs RJ, Andreassen TT CALCIF TISSUE INT 2001 68 2 95-101
7. 2 to stimulate bone growth in ovariectomized rats. Whitfield JF, Morley P, Willick G, Langille R, Ross V, MacLean S, Barbier JR J BONE MINER RES 1997 12 8 1246-1252
8. 2 to stimulate femoral trabecular bone growth in ovariectomized rats. Whitfield JF, Morley P, Willick GE, Ross V, MacLean S, Barbier JR, Isaacs RJ, Ohannessian-Barry L CALCIF TISSUE INT 1997 60 1 26-29
9. 505583 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ N ENGL J MED 2003 349 13 1207-1215
10. 581435 Nektar to develop inhaled parathyroid hormone for Zelos Nektar Therapeutics PRESS RELEASE 2005 January 24
11. 602365 Zelos raises $42.5 million from financing round. Zelos Therapeutics Inc PRESS RELEASE 2005 May 18
12. 613872 Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Schietert HR, Groen EWJ, Sollie FAE, Jonkman JHG CLIN PHARMACOL THERAP 1997 61 3 360-376
13. 638841 Modified bacterial mutation test procedures for evaluation of peptides and amino acid-containing material. Thompson C, Morley P, Kirkland D, Proudlock R MUTAGENESIS 2005 20 5 345-350
14. 847531 Ostabolin-C: A novel parathyroid hormone analogue uncouples bone turnover in monkeys treated for 1-year. Jolette J, Smith SY, Moreau IA, Turner CH, Mayer J, Rushton B, Morley P J BONE MINER RES 2005 20 9
15. 886897 BA058, a novel analog of human parathyroid hormone-related peptide (PTHrP), induces evidence of bone formation without evidence of bone resorption over 7 days of exposure. O'Dea L, Lyttle CR, Rosen CJ ANN MEET ENDOCRINE SOC 2007 89 Abs P2-P137
16. 897547 Zelos to use Aegis' Intravail technology to develop a new formulation of ZT-031 Zelos Therapeutics Inc PRESS RELEASE 2008 April 16
17. 897603 Form 10-K for the fiscal year ended December 31, 2007 Nektar Therapeutics FORM 10-K 2008 February 29
18. 904512 Pulmonary delivery of the parathyroid hormone analogue Ostabolin-C stimulates markers of bone formation in postmenopausal women. Morley P, Bishop J, Anderson R, Barclay CL, Krause D, Morelli G, Newhouse M, Sadrzadeh N, Eldon M J BONE MINER RES 2007 22 Suppl 1 Abs M421
19. 904515 Ostabolin-C increases lumbar spine and hip BMD after 1 year of therapy: Results of a phase II clinical trial. Hodsman A, Bone H, Gallagher C, Kendler D, Brown JP, Greenspan S, Barclay CL, Morley P, Anderson R, MacDonald BR J BONE MINER RES 2007 22 Suppl 1 Abs 1130
20. 927808 Zelos receives US and EU approval for phase III ZT-031 trial for osteoporosis. Zelos Therapeutics Inc Press Release 2008 July 24
21. 932987 Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA J BONE JOINT SURG AM 2005 87 4 731-741
22. 933000 Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31) and monocyclic hPTH(1-31) enhances fracture strength and callus amount - after withdrawal fracture strength and callus mechanical quality continue to increase. Andreassen TT, Willick GE, Morley P, Whitfield JF CALCIF TISSUE INT 2004 74 4 351-356
23. 933006 Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: Cyclic lactams of the receptor binding regions. Barbier JR, Neugebauer W, Morley P, Ross V, Soska M, Whitfield JF, Willick G J MED CHEM 1997 40 9 1373-1380
24. 933007 Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM J CLIN ENDOCRINOL METAB 2006 91 4 1370-1375
25. 933009 Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. Brommage R, Hotchkiss CE, Lees CJ, Stancill MW, Hock JM, Jerome CP J CLIN ENDOCR METAB 1999 84 10 3757-3763
26. 933010 Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM J BONE MINER RES 2001 16 1 157-165
27. 933011 Mechanisms of anabolic therapies for osteoporosis. Canalis E, Giustina A, Bilezikian JP NEW ENGL J MED 2007 357 9 905-916
28. 933016 Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Dean T, Vilardaga JP, Potts JT Jr, Gardella TJ MOLEC ENDOCR 2008 22 1 156-166
29. 933017 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM NEW ENGL J MED 2003 349 13 1216-1226
30. 933020 Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Fox J, Miller MA Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY CALCIF TISSUE INT 2006 79 4 262-272
31. 933021 Treatment of skeletally-mature ovariectomized rhesus monkeys with parathyroid hormone (1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY J BONE MINER RES 2007 22 2 260-273
32. 933023 Effects of treatment of ovariectomized adult rhesus monkeys with parathyroid hormone 1-84 for 16 months on trabecular and cortical bone structure and biomechanical properties of the proximal femur. Fox J, Miller MA, Recker RR, Turner CH, Smith SY CALCIF TISSUE INT 2007 81 1 53-63
33. 933024 Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY BONE 2007 41 3 321-330
34. 933027 Cell-specific signaling and structure-activity relations of parathyroid hormone analogs in mouse kidney cells. Friedman PA, Gesek FA, Morley P, Whitfield JF, Willick GE ENDOCR 1999 140 1 301-309
35. 933028 Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsberger PL, Sato M, Hock JM BONE 2003 33 3 372-379
36. 933391 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB ANN INT MED 2007 146 5 326-339
37. 933392 Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E et al ENDOCR REv 2005 26 5 688-703
38. 933393 Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF J CLIN ENDOCR METAB 2003 88 2 569-575
39. 2 vitamin D. Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocaña A, Bisello A, Hollis BW, Rosen CJ, Wysolmerski JJ, Dann P, Gundberg C et al J BONE MINER RES 2005 20 10 1792-1803
40. 933398 Defining a non-carcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS TOXICOL PATHOL 2006 34 7 929-940
41. 933399 Further definition of the protein kinase C activation domain of the parathyroid hormone. Jouishomme H, Whitfield JF, Gagnon L, Maclean S, Isaacs R, Chakravarthy B, Durkin J, Neugebauer W, Willick G, Rixon RH J BONE MINER RES 1994 9 6 943-949
42. 933466 New concepts in drug discovery: Collateral efficacy and permissive antagonism. Kenakin T NAT REV DRUG DISCOV 2005 4 11 919-927
43. 933474 Building bone to reverse osteoporosis and repair fractures. Khosla S, Westendorf JJ, Oursler MJ J CLIN INVEST 2008 118 2 421-428
44. 933483 Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone (1-34): Kinetics and biochemical response in estrogenized osteoporotic patients. Lindsay R, Nieves J, Henneman E, Shen V, Cosman F J CLIN ENDOCR METAB 1993 77 6 1535-1539
45. 933487 Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Martin TJ, Sims NA, Ng KW OSTEOPOROSIS INT 2008 19 8 1125-1138
46. 933489 Biological activity of recombinant PTH analog UGL7841. Mehta NM, Gilligan JP, Stern B, Ray MVL, Meenan CP, Consalvo AP, Peng X, Vignery A, Ross V, Whitfield JF, Morley P AM SOC BONE MINER RES 2002 September 20-24
47. 933498 Clinical use of teriparatide in the real world: Initial insights. Miller PD, Bilezikian JP, Deal C, Harris ST, Pacifici R ENDOCR PRAC 2004 10 2 139-148
48. 933503 Prolonged low-dose infusion of human parathyroid hormone does not increase femoral cancellous bone volume in ovariectomized rats. Morley P, Whitfield JF, Willick GE, Ross V, MacLean S, Isaacs RJ, Mendoza E, Barbier JR EUR J ENDOCRINOL 1999 141 1 70-74
49. 933508 The parathyroid polyhormone hypothesis revisited. Nemeth EF KIDNEY INTL 2006 70 102 22-S28
50. 933515 Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y BONE 2008 42 1 90-97
51. 933517 Structure-based design of parathyroid hormone analogs. Potts JT Jr, Gardella TJ, Jüppner H, Kronenberg HM J ENDOCR 1997 154 S15-S21
52. 933520 hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological response. Reeve, J, Bradbeer JN, Arlot M, Davies UM, Green JR, Hampton L, Edouard C, Hesp R, Hulme P, Ashby JP, Zanelli JM et al OSTEOPOROSIS INT 1991 1 3 162-170
53. 933522 Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase. Rixon RH, Whitfield JF, Gagnon L, Isaacs RJ, Maclean S, Chakravarthy B, Durkin JP, Neugebauer W, Ross V, Sung W, Willick GE J BONE MINER RES 1994 9 8 1179-1189
54. 933527 Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH J BONE MINER RES 2004 19 4 623-629
55. 933806 Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. Tashjian AH Jr, Gagel RF J BONE MIN RES 2006 21 3 354-365
56. 933807 On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84). Tashjian AH Jr, Goltzman D J BONE MINER RES 2008 23 6 803-811
57. 933809 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB TOXICOL PATHOL 2002 30 3 312-321
58. 933810 Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M TOXICOL PATHOL 2004 32 4 426-438
59. 933811 Variations in animal populations over time and differences in diagnostic thresholds used can impact tumor incidence data. Vahle JL, Sato M, Long GG TOXICOL PATHOL 2007 35 7 1045-1046
60. 2. Whitfield JF, Isaacs R, MacLean S, Morley P, Barbier JR, Willick GE CELL SIGNAL 1999 11 3 159-164
61. 933817 Stimulation of protein kinase C activity in cells expressing human parathyroid hormone receptors by C- and N-terminally truncated fragments of parathyroid hormone 1-34. Whitfield JF, Isaacs RJ, Chakravarthy B, Maclean S, Morley P, Willick G, Divieti P, Bringhurst FR J BONE MINER RES 2001 16 3 441-447
62. 933827 The effects of parathyroid hormone (PTH) fragments on bone formation and the initiation of colon carcinogenesis in rats as indicated by preneoplastic aberrant crypt formation. Whitfield J, Bird RP, Morley P, Willick GE, Barbier JR, MacLean S, Ross V CANCER LETTERS 2003 200 2 107-113
63. 933828 Constrained analogues of osteogenic peptides. Willick GE, Morley P, Whitfield JF CURR MED CHEM 2004 11 2599-2613
64. 933829 Parathyroid hormone activates PKC-δ and regulates osteoblastic differentiation via a PLC-independent pathway. Yang D, Guo J, Divieti P, Bringhurst FR BONE 2006 38 4 485-496
65. 933839 Ostabolin-C: A novel parathyroid hormone analogue uncouples bone turnover in monkeys. Jolette J, Smith SY, Mayer J, Green C, Rushton B, Morley P AM SOC BONE MINER RES 2003 25 September 19-23
66. 935482 PTH analogs enhance bone formation at a weight-bearing cement-bone interface. Allen MJ, Schoonmaker JE, Mann KA, Ross V, Allen C, Morley P, Willick GE, Whitfield JF ORTHOPEDICS RESEARCH SOCIETY 2004
67. 935483 Ostabolin-C: A phase I trial to assess its safety, tolerability and pharmacokinetics in healthy older adults. Barclay L, Anderson R, Champoux-Knott L, Morelli G, Morley P INT OSTEOPOROSIS FOUND (IOF) WORLD CONGRESS OSTEOPOROSIS 2006 June 2-6
68. 935484 A novel parathyroid hormone analogue increases bone formation and strength in rats treated for 26 weeks. Morley P, Jolette J, Smith SY, Turner CH, Moreau I, Mayer J INT OSTEOPOROSIS FOUND (IOF) WORLD CONGRESS OSTEOPOROSIS 2006 June 2-6
69. 2 to stimulate femoral trabecular bone growth in ovariectomized rats. Whitfield JF, Morley P, Willick G, MacLean S, Ross V, Isaacs RJ, Barbier JR CALCIF TISS INT 1998 63 5 423-428
70. 936046 Who are candidates for prevention and treatment for osteoporosis? No Authors Listed OSTEOPOROSIS INT 1997 7 1 1-6
71. 936047 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A J BONE MINER RES 2007 22 3 465-475
72. 936053 Bone health and osteoporosis: A report of the surgeon general. US DEPARTMENT HEALTH HUM SERVICES 2004 October 14
73. 936261 Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Epstein S CLIN THER 2006 28 2 151-173
74. 936280 Developments in parathyroid hormone and related peptides as bone-formation agents. Fox J CURR OPIN PHARMACOL 2002 2 3 338-344
75. 936281 Parathyroid hormone and parathyroid hormone-related peptide and their receptors. Gensure RC, Gardella TJ, Jüppner H BIOCHEM BIOPHYS RES COMMUN 2005 328 3 666-678
76. 936298 FDA approves teriparatide to treat osteoporosis. The US Food & Drug Administration PRESS RELEASE 2002 November 26
77. 936299 European public assessment report (EPAR): Forsteo. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2007 July
78. 936319 Committee for medicinal products for human use post-authorisation summary of positive opinion for Forsteo. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2008 February 21
79. 936329 European public assessment report (EPAR): Preotact. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2006 March
80. 936333 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF J BONE MINER RES 2005 20 7 1244-1253
81. 937055 The protein kinase-C activation domain of the parathyroid hormone. Jouishomme H, Whitfield JF, Chakravarthy B, Durkin JP, Gagnon L, Isaacs RJ, MacLean S, Neugebauer W, Willick G, Rixon RH ENDOCRINOLOGY 1992 130 1 53-60
82. 937059 Type-1 parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptors activate phospholipase C in response to carboxyl-truncated analogs of PTH(1-34). Takasu H, Bringhurst FR ENDOCRINOLOGY 1998 139 10 4293-4299
83. 937066 Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. The US Food & Drug Administration FDA GUIDELINES 1994 April
84. 937068 Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2006 November 16
85. 2. Whitfield JF, Morley P, Fraher L, Hodsman AB, Holdsworth DW, Watson PH, Willick GE, Barbier JR, Gulam M, Isaacs RJ, Ross V et al CALCIF TISSUE INT 2000 66 4 307-312
86. 938044 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF J CLIN ENDOCRINOL METAB 2005 90 7 3970-3977
87. 938069 Emerging indications: Renal bone disease. Zelos Therapeutics Inc COMPANy wORLD WIDE WEB SITE 2008 August 26
88. 938089 Adynamic bone in patients with chronic kidney disease. Andress DL KIDNEY INT 2008 73 12 1345-1354
89. 939739 Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF J CLIN ENDOCRINOL METAB 2003 88 4 1603-1609
90. 939787 Fracture repair. Zelos Therapeutics Inc COMPANy WORLD WIDE WEB SITE 2008 Sept 02
91. 940241 Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. Iida-Klein A, Lu SS, Kapadia R, Burkhart M, Moreno A, Dempster DW, Lindsay R J ENDOCRINOL 2005 186 3 549-557
92. 940243 Parathyroid hormone secretion and action: Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Murray TM, Rao LG, Divieti P, Bringhurst FR ENDOCR REV 2005 26 1 78-113
93. 940247 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB J BONE MINER RES 2005 20 6 962-970
94. 940262 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: Results from a 6-month double-blind placebo-controlled trial. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH J BONE MINER RES 2005 20 11 1905-1911
95. 945181 Structure-activity relations in the calcium-regulating peptide hormones. Rosenblatt M ENDOCRINOLOGY OF CALCIUM METABOLISM (EDS: PARSONS JA) 1982 Raven Press, New York 103-142
96. 2 (Ostabolin). Whitfield JF, Morley P, Willick GE, Ross V, Barbier JR, Isaacs RJ, Ohannessian-Barry L CALCIF TISSUE INT 1996 58 2 81-87
97. 945499 Chapter 8: Osteitis fibrosa, osteomalacia and mixed bone lesions. Felsenfeld AJ, Torres A The Spectrum of Renal Osteodystrophy (EDS: DRÜEKE T, SALUSKY I) 2001 Oxford University Press, Oxford, UK 185-226
98. 945540 K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation Inc AM J KIDNEY DIS 42 suppl 3 1-201
99. 946168 Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. Henry JG, Mitnick M, Dann PR, Stewart AF J CLIN ENDOCRINOL METAB 1997 82 3 900-906
100. 946187 Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: Potential as an anabolic therapy for osteoporosis. Plotkin H, Gundberg C, Mitnick M, Stewart AF J CLIN ENDOCRINOL METAB 1998 83 8 2786-2791
101. 946193 The use of parathyroid hormone in the treatment of osteoporosis. Girotra M, Rubin MR, Bilezikian JP REV ENDOCRINE METAB DISORDERS 2006 7 1-2 113-121
102. 947347 Pipeline: Osteoporosis. Zelos Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2008 September 30
103. 949331 Synthesis for ZT-031. Zelos Therapeutics Inc COMPANY COMMUNICATION 2008 October 06 • Gene Merutka of Zelos Therapeutics provided a general outline of the synthesis used to produce ZT-031.